OBJECTIVES: To investigate the frequency and severity of side effects of methylphenidate among childhood survivors of acute lymphoblastic leukemia and brain tumors and identify predictors of higher adverse effect levels. METHODS:Childhood cancer survivors (N = 103) identified as having attention and learning problems completed a randomized, double-blind, 3-week, home-crossover trial of placebo, low-dose methylphenidate (0.3 mg/kg; 10 mg twice daily maximum) and moderate-dose methylphenidate (0.6 mg/kg; 20 mg twice daily maximum). Caregivers completed the Barkley Side Effects Rating Scale (SERS) at baseline and each week during the medication trial. Siblings of cancer survivors (N = 49) were recruited as a healthy comparison group. RESULTS: There was a significantly higher number and severity of symptoms endorsed on the SERS when patients were taking moderate dose compared with placebo or low dose, but not low dose compared with placebo. The number of side effects endorsed on the SERS was significantly lower during all 3 home-crossover weeks (placebo, low dose, moderate dose) when compared with baseline symptom scores. The severity of side effects was also significantly lower, compared with baseline screening, during placebo and low-dose weeks but not moderate-dose weeks. Both the number and severity of symptoms endorsed at baseline were significantly higher for patients compared with siblings. Female gender and lower IQ were associated with higher adverse effect levels. CONCLUSIONS:Methylphenidate is generally well tolerated by childhood cancer survivors. There is a subgroup at increased risk for side effects that may need to be closely monitored or prescribed a lower medication dose. The seemingly paradoxical findings of increased "side effects" at baseline must be considered when monitoring side effects and designing clinical trials.
RCT Entities:
OBJECTIVES: To investigate the frequency and severity of side effects of methylphenidate among childhood survivors of acute lymphoblastic leukemia and brain tumors and identify predictors of higher adverse effect levels. METHODS:Childhood cancer survivors (N = 103) identified as having attention and learning problems completed a randomized, double-blind, 3-week, home-crossover trial of placebo, low-dose methylphenidate (0.3 mg/kg; 10 mg twice daily maximum) and moderate-dose methylphenidate (0.6 mg/kg; 20 mg twice daily maximum). Caregivers completed the Barkley Side Effects Rating Scale (SERS) at baseline and each week during the medication trial. Siblings of cancer survivors (N = 49) were recruited as a healthy comparison group. RESULTS: There was a significantly higher number and severity of symptoms endorsed on the SERS when patients were taking moderate dose compared with placebo or low dose, but not low dose compared with placebo. The number of side effects endorsed on the SERS was significantly lower during all 3 home-crossover weeks (placebo, low dose, moderate dose) when compared with baseline symptom scores. The severity of side effects was also significantly lower, compared with baseline screening, during placebo and low-dose weeks but not moderate-dose weeks. Both the number and severity of symptoms endorsed at baseline were significantly higher for patients compared with siblings. Female gender and lower IQ were associated with higher adverse effect levels. CONCLUSIONS:Methylphenidate is generally well tolerated by childhood cancer survivors. There is a subgroup at increased risk for side effects that may need to be closely monitored or prescribed a lower medication dose. The seemingly paradoxical findings of increased "side effects" at baseline must be considered when monitoring side effects and designing clinical trials.
Authors: Heather M Conklin; Raja B Khan; Wilburn E Reddick; Susan Helton; Ronald Brown; Scott C Howard; Melanie Bonner; Robbin Christensen; Shengjie Wu; Xiaoping Xiong; Raymond K Mulhern Journal: J Pediatr Psychol Date: 2007-06-14
Authors: Robert W Butler; Donna R Copeland; Diane L Fairclough; Raymond K Mulhern; Ernest R Katz; Anne E Kazak; Robert B Noll; Sunita K Patel; Olle Jane Z Sahler Journal: J Consult Clin Psychol Date: 2008-06
Authors: Heather M Conklin; Jason M Ashford; Kellie N Clark; Karen Martin-Elbahesh; Kristina K Hardy; Thomas E Merchant; Robert J Ogg; Sima Jeha; Lu Huang; Hui Zhang Journal: J Pediatr Psychol Date: 2017-03-01
Authors: Heather M Conklin; Robert J Ogg; Jason M Ashford; Matthew A Scoggins; Ping Zou; Kellie N Clark; Karen Martin-Elbahesh; Kristina K Hardy; Thomas E Merchant; Sima Jeha; Lu Huang; Hui Zhang Journal: J Clin Oncol Date: 2015-10-12 Impact factor: 44.544
Authors: Heather M Conklin; Wilburn E Reddick; Jason Ashford; Susan Ogg; Scott C Howard; E Brannon Morris; Ronald Brown; Melanie Bonner; Robbin Christensen; Shengjie Wu; Xiaoping Xiong; Raja B Khan Journal: J Clin Oncol Date: 2010-09-13 Impact factor: 44.544
Authors: Sharon M Castellino; Janet A Tooze; Lynn Flowers; Debbie F Hill; Kevin P McMullen; Edward G Shaw; Susan K Parsons Journal: Pediatr Blood Cancer Date: 2012-01-11 Impact factor: 3.167
Authors: Raja B Khan; Maha Bano; Fang Wang; Pan Haitao; Anthony Christensen; Jessica Smith; Andrea Simmons; Zsila S Sadighi Journal: Pediatr Blood Cancer Date: 2020-10-13 Impact factor: 3.167